1 Digital Healthcare Stock To Avoid
Health services IT company TRxADE HEALTH, Inc. (NASDAQ:MEDS) played a vital role during the pandemic, making remote care and tests available to patients with its digital healthcare wing. While the effects of the pandemic are largely in the rearview mirror, TRxADE remains a prominent player in the pharmaceutical industry. » Read more about: 1 Digital Healthcare Stock To Avoid »
Read More
3 Compelling Reasons to Buy Google’s Parent
Google is the most visited website on earth, attracting billions of users who rely on it to carry out their daily searches. However, Google’s parent, Alphabet (NASDAQ:GOOGL), is much more than just a search engine. From Gmail to Google Drive, Google provides a host of tools and apps — many of which reinvented how we access information.
» Read more about: 3 Compelling Reasons to Buy Google’s Parent »
Read More
1 High Potential Growth Stock To Avoid Now
As markets dropped at the beginning of 2022, growth stocks took a nosedive. Even big name firms got a severe haircut. Netflix (NFLX) fell by more than 70%, Salesforce (CRM) dropped by over 36%, and Meta Platforms Inc. (META) plummeted more than 52%.
» Read more about: 1 High Potential Growth Stock To Avoid Now »
Read More
1 Huge Reason to Steer Clear of This Stock
Target is one of America’s largest retailers — and while the brand is a name consumers know and love, investors have a different perspective lately. The big-box retailer is facing significant inventory issues. These are so troublesome that Target altered its guidance weeks after issuing it.
As an investor, here’s what you need to know about Target now and moving forward.
» Read more about: 1 Huge Reason to Steer Clear of This Stock »
Read More
Stunning Win-Win Deal For Top Magnificent 7 Stocks
In stunning news announced earlier this week, Apple revealed that it is looking to partner with Alphabet to allow Google’s Gemini to power iPhone AI features.
The announcement was stunning on numerous counts. Notably, both stocks ended the trading higher on the news. That fact alone suggests that the market interprets the deal to be a win-win.
» Read more about: Stunning Win-Win Deal For Top Magnificent 7 Stocks »
Read MoreThe Burst
Market Commentary: The Meteoric Rise of Eli Lilly
Did you know that Eli Lilly and other pharmaceutical companies have sold approximately 10.6 million shots of obesity drug doses in the U.S. in a single month? The rise of these injectable weight loss medications is so powerful that it’s causing investors to question the future of even staple food and beverage stocks.
While this aspect alone could secure Eli Lilly as the pharmaceutical golden goose you’ve been looking for there is much more than meets the eye.
» Read more about: Market Commentary: The Meteoric Rise of Eli Lilly »
Read MoreThe Spotlight
Is Peloton Finally a Buy?
» Read more about: Is Peloton Finally a Buy? »
Read MoreThe Daily
US economic growth slows despite consumers spending more
His plans include big cuts to government spending and implementing trade tariffs, which could be announced this week.
The US economy had been forecast to expand at roughly 2.5% in the final three months of 2024 though analysts said details of the Commerce Department report suggested growth remained solid.
“The US consumer has been unstoppable,
» Read more about: US economic growth slows despite consumers spending more »